These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. Pelak BA; Citron DM; Motyl M; Goldstein EJ; Woods GL; Teppler H J Antimicrob Chemother; 2002 Nov; 50(5):735-41. PubMed ID: 12407133 [TBL] [Abstract][Full Text] [Related]
6. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ertapenem: review of recent studies. Wexler HM J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179 [TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of trospectomycin (U-63,366F) against anaerobic bacteria and aerobic gram-positive cocci in Chile. Montiel F; Kaltwasser G; Pinto ME; Lam M Diagn Microbiol Infect Dis; 1991; 14(3):259-64. PubMed ID: 1832369 [TBL] [Abstract][Full Text] [Related]
9. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. Cheng AF; Ling TK; Lam AW; Fung KS; Wise R J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498 [TBL] [Abstract][Full Text] [Related]
10. HRE 664, a new parenteral penem. I. Antibacterial activity in vitro. Seibert G; Isert D; Klesel N; Limbert M; Pries A; Schrinner E; Cooke M; Walmsley J; Bentley PH J Antibiot (Tokyo); 1987 May; 40(5):660-7. PubMed ID: 3497140 [TBL] [Abstract][Full Text] [Related]
11. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Chin NX; Neu HC Antimicrob Agents Chemother; 1984 Mar; 25(3):319-26. PubMed ID: 6232895 [TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of the new oxacephem antibiotic, flomoxef (6315-S). Ruckdeschel G; Eder W Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):687-91. PubMed ID: 3143586 [TBL] [Abstract][Full Text] [Related]
13. [Preclinical evaluation of meropenem, a new parenteral carbapenem]. Edwards JR New Microbiol; 1995 Oct; 18 Suppl():19S-31S. PubMed ID: 8574929 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in-vitro antibacterial activity of Sch 34343. Adam C; Naples L; Weiss W; Sabatelli F; Hare R; Loebenberg D; Miller GH J Antimicrob Chemother; 1985 Jun; 15 Suppl C():39-56. PubMed ID: 3875604 [TBL] [Abstract][Full Text] [Related]
15. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Barlam T; Neu HC Antimicrob Agents Chemother; 1984 Apr; 25(4):529-31. PubMed ID: 6732223 [TBL] [Abstract][Full Text] [Related]
16. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics. Phillips I; Warren C; Shannon K; King A; Hanslo D J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967 [TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of the new oral cephalosporin Bay v 3522 against aerobic and anaerobic bacteria. Rylander M; Nord CE; Norrby SR Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):777-82. PubMed ID: 2261923 [TBL] [Abstract][Full Text] [Related]
18. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006]. Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596 [TBL] [Abstract][Full Text] [Related]
19. [Antimicrobial susceptibility of clinical isolates of aerobic gram-positive cocci and anaerobic bacteria in 2008]. Yoshida I; Yamaguchi T; Kudo R; Fuji R; Takahashi C; Oota R; Kaku M; Kunishima H; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Fujita S; Matsuo S; Kono H; Asari S; Toyokawa M; Kusano N; Nose M; Horii T; Tanimoto A; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y Jpn J Antibiot; 2012 Feb; 65(1):49-72. PubMed ID: 22808693 [TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Goldstein EJ; Citron DM; Merriam CV; Tyrrell KL Diagn Microbiol Infect Dis; 2013 Jul; 76(3):347-51. PubMed ID: 23623385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]